Sage Therapeutics to Present at American Academy of Neurology 2017 Annual Meeting

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations for brexanolone (SAGE-547) and SAGE-217 at the American Academy of Neurology (AAN) 2017 Annual Meeting, taking place April 22-28, 2017 in Boston, Mass.

Below is the schedule for the presentations:

Date: April 25, 2017Poster Presentation Time: 8:30 a.m.-7:00 p.m. ETLocation: Poster Hall, Neighborhood APoster Number: P3.008Title: The pharmacokinetics of SAGE-217 in Phase 1 SAD and MAD studies

Date: April 25, 2017Poster Presentation Time: 8:30 a.m.-7:00 p.m. ETLocation: Poster Hall, Neighborhood APoster Number: P3.009Title: Next-generation neuroactive steroid SAGE-217 in a multiple-ascending dose study

Date: April 25, 2017Poster Presentation Time: 8:30 a.m.-7:00 p.m. ETLocation: Poster Hall, Neighborhood GPoster Number: P3.224Title: Evaluation of the costs, length of stay, and mortality associated with super-refractory status epilepticus in Germany

Date: April 27, 2017Poster Presentation Time: 8:30 a.m.-7:00 p.m. ETLocation: Poster Hall, Neighborhood APoster Number: P5.021Title: Preclinical characterization of SAGE-217 in a rodent model of oral dyskinesia

Date: April 28, 2017Poster Presentation Time: 8:30 a.m.-5:30 p.m. ETLocation: Poster Hall, Neighborhood APoster Number: P6.017Title: Next-generation neuroactive steroid SAGE-217 in a single-ascending dose study

Date: April 28, 2017Poster Presentation Time: 8:30 a.m.-5:30 p.m. ETLocation: Poster Hall, Neighborhood BPoster Number: P6.068Title: Preclinical pharmacology and pharmacodynamic interactions of SAGE-547: Relevance to super-refractory status epilepticus (SRSE)

Date: April 28, 2017Poster Presentation Time: 8:30 a.m.-5:30 p.m. ETLocation: Poster Hall, Neighborhood GPoster Number: P6.234Title: Hemodynamic properties of SAGE-547 in patients with super-refractory status epilepticus: results from a Phase 1/2 clinical trial

Date: April 28, 2017Poster Presentation Time: 8:30 a.m.-5:30 p.m. ETLocation: Poster Hall, Neighborhood GPoster Number: P6.241Title: Pharmacokinetics of SAGE-547 in patients with super-refractory status epilepticus

About Sage TherapeuticsSage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, brexanolone (SAGE-547), is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170419005287/en/

Investor Contact:Sage TherapeuticsPaul Cox, [e-mail] Contact:Suda Communications LLCMaureen L. Suda, [e-mail]